Loading…
Loading…
6652.TWO (Eusol Biotech Co.,Ltd.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
6652.TWO does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 6652.TWO and 80,000+ other tickers.
See exactly how 6652.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6652.TWO and 80,000+ other tickers.
Eusol Biotech Co.,Ltd. is a biopharmaceutical firm primarily dedicated to the discovery and advancement of innovative biotechnological treatments for various sleep-related conditions. Its current development portfolio showcases two key candidates: ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) designed to restore and repair neuronal function; and SM-1, a singular capsule formulation that combines three commercially available sedative medications. The company commenced operations in 1994 and maintains its principal offices in Taipei, Taiwan.
No recent news available.